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Objectives: Assessment of costs of CF with regards to lung disease severity within
the Czech (CZ) health care (HC).
Methods: CF registry and health insurance data drawn from the Prague CF centre
(accounting for >60% of all patients) allowed prevalence-based cost of Illness
analysis. We studied 267 cases stratiﬁed by their age, gender, CFRD, oxygen
therapy and FEV1% [“mild” (>70% predicted); “moderate” (40%< and 70%);
“severe” (40%)]. HC costs were considered within (a) in/outpatient care/surgery,
(b) pharmacotherapy/medical devices, (c) lab. examination. Multivariate regression
identiﬁed main “cost drivers”.
Results: Average (median) patients age was 17.4 (16.0) years. Total mean (median)
annual costs were equal to €4,272 (€977; in 2009 prices). As expected, there
is a trend towards increased costs in severe cases. The mean (median) costs
of mild, moderate and severe CF were €2,722 (€896), €6,508 (€1,084), and
€12,956 (€5,944), respectively (p< 0.001). The costs of medication and devices,
examinations, and in/outpatient costs were: in the case of mild CF (€881, €1,204,
€837), moderate CF (€2,073, €2,169, €2,730) and severe CF (€5,389, €2,444,
€5,900), respectively. Patients with moderate and severe CF had higher total costs
by 52% (p = 0.027) and by 140% (p< 0.001) compared to mild cases. Females and
patients with CFRD had higher total costs.
Conclusions: Costs of CF care (a) could be stratiﬁed according to lung disease
severity, (b) are lower compared to other countries and (c) form basic understanding
for the introduction of CFTR-modulation therapies.
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While previous analysis have compared the efﬁcacy of differencent physiotherapy modalities, their
cost effectiveness has not been studied.
Objective: The purpose of this study was to examine the economic cost of two airway clearance
techniques (ACT) namely Positive Expiratory Pressure (PEP) and High Frequency Chest Wall
Oscillation (HFCWO.
Methods: As part of a larger study 107 patients were enrolled in this study and randomized to either
performing PEP or HFCWO for a one year period. Pulmonary exacerbation (PE) was the primary
outcome. All costs associated with PEs was recorded including cost of hospitalizations, antibiotics
either IV, inhaled or oral and cost of device.
Results: 42 subjects completed the study in the PEP group and 46 in the HFCWO group. There
were 6 PEs in the PEP group requiring IV antibiotics versus 19 PEs in the HFCWO group. Table 1
outlines associated costs.
Table 1. Cost of performing PEP vs. HFCWO
Antibiotic route PEP (N= 42) HFCWO (N= 46)
Number of
exacerbations
Cost Number of
exacerbations
Cost
IV 6 (14 IV drugs) $8,955 19 (40 IV drugs) $16,096
Inhaled 4 $16,865 5 $16,128
Oral 35 (39 drugs) $891 58 (68 drugs) $1,105
All antibiotics $26,711 $33,329
Total number of hospital days 76@$1,120 $85,120 191@$1,120 $213,920
Total number of days on home IV 9@$500 $4,500 96@$500 $48,000
Total treatment cost $116,331 for 42 pts
= $2,770 per pt
$295,249 for 46 pts
= $6,419 per pt
Device cost $75 $14,000
Total medical cost per patient $2,845 for one year $20,419 for one year
The average medical cost for one year using HFCWO was $20,419 compared to $2,845 for using
PEP. This comparison does not include the economic cost of missed school or work days.
Conclusion: The use of HFCWO as an ACT signiﬁcantly increases healthcare costs compared to
PEP.
